2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1472

Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting
Abstract Number: 197

Discordance Of Patient-Physician Assessments Of General Health In a US Hispanic Population With Rheumatoid Arthritis
Abstract Number: 1427

Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Abstract Number: 1491

Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren’s Syndrome Patients
Abstract Number: 1832

Discovery of MicroRNAs in the Regulation of Inflammation and Bone Erosion in Rheumatoid Arthritis
Abstract Number: 2416

Discovery Of Novel Biomarkers In Rheumatoid Urine : Significance Of Urinary CD14
Abstract Number: 1326

Discriminative Metabolite Profiling Of Synovial Fluid In Rheumatoid Arthritis Compared To Osteoarthritis
Abstract Number: 2401

Disease Activity (DAS-28CRP) In Rheumatoid Arthritis Correlates With Synovial Expression Of Tumor-Associated and IL-6-Dependent Genes
Abstract Number: 2541

Disease Activity Does Not Improve Significantly In One System and Worsen In Another System
Abstract Number: 1510

Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis
Abstract Number: 2318

Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Abstract Number: 422

Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Abstract Number: 2447

Disease Activity Is Associated With Development Of Inflammatory Bowel Disease In Ankylosing Spondylitis: 12-Year Results From OASIS
Abstract Number: 1356

Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Abstract Number: 2299

Disease Activity Scoring: Comparing Patient and Physician Global Assessment Of Disease Activity In Rhumatoid Arthritis Patients Starting a First Biologic Agent

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].